Engineered immune cells take on childhood leukemia in new trial

NCT ID NCT04276870

Recruiting now Disease control Sponsor: Stephan Grupp MD PhD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a personalized cell therapy called CART19 in children and young adults with certain high-risk forms of B-cell acute lymphoblastic leukemia (B-ALL). The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The study aims to see if this treatment can improve event-free survival—meaning keeping the cancer from coming back—in patients who have limited options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CART19 cells (a type of CAR T-cell therapy made from the patient's own immune cells)
What this could lead to: If successful, this could offer a powerful treatment option for children with aggressive or relapsed B-ALL who have few alternatives.
What could go wrong: This is a mid-stage trial with a relatively small number of participants. CAR T-cell therapy can cause severe side effects like cytokine release syndrome, and long-term outcomes are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia B-cell childhood acute lymphoblastic leukemia B-lymphoblastic leukemia/lymphoma with hypodiploidy B-lymphoblastic leukemia/lymphoma with t(17;19) B-lymphoblastic leukemia/lymphoma with t(v;11q23.3) central nervous system leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFANTS WITH VERY HIGH RISK KMT2A B-ALL PATIENTS WITH CENTRAL NERVOUS SYSTEM RELAPSE WHO DID NOT RECEIVE CRANIAL RADIATION OR BONE MARROW TRANSPLANTATION PEDIATRIC AND YOUNG ADULT PATIENTSWITH HYPODIPLOID OR T(17;19) B-ALL

Contacts and locations

Locations

Children's Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.